Clinical Trial

Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is1. Compare the differences in the changes of glycated hemoglobin after 24 weeks of treatment between the new metformin sustained-release tablets (Ⅲ) group and the metformin ordinary tablets group. 2\. Compare the differences in the changes of fasting blood glucose, gastrointestinal adverse reactions of the drug and compliance after 24 weeks of treatment between the new metformin sustained-release tablets (Ⅲ) group and the metformin ordinary tablets group.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-10; most recent amendment 2025-04-26.
Trial Details
NCT Number NCT06932874
Lead Sponsor China National Center for Cardiovascular Diseases
Conditions Atherosclerotic Heart Disease, Type 2 Diabetes
Enrollment 356 participants
Start Date 2025-03-04
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-30